Photo: Aldo Murillo/Getty Images
splose bags $32M Series A funding
Allied health software provider splose has raised A$46 million ($32 million) in a Series A funding round led by United States-based growth equity firm Spectrum Equity, with participation from Athletic Ventures.
The company, founded in 2018, offers an end-to-end practice management platform, positioned as an "operating system for allied health practices." Used by more than 20,000 allied health professionals across Australia, the United Kingdom, and New Zealand, it supports booking, payments, invoicing, and reporting.
In a statement, splose said it will use its fresh funds to further expand across Australia and the UK, scale teams in Adelaide, Sydney, Melbourne and London, accelerate deeper AI integration to streamline practitioner workflows, and facilitate seamless payment processing.
Wellumio scores $4M for stroke imaging
New Zealand medical device company Wellumio has raised NZ$7.28 million ($4.3 million) in the first close of its pre-Series A funding round to accelerate the development of its portable, AI-augmented stroke imaging device.
Its battery-powered brain imaging device utilises Pulsed Gradient Free Mapping technology, which received a patent in the United States in December 2025, to generate MRI-based stroke biomarkers at the point of care without the need for contrast agents, cryogenics, or shielded rooms.
Based on a media release, the newly raised funds will be used to expand the clinical evaluation of its AI-powered stroke imaging device across additional sites and geographies.
Australia, UK clear Alcidion's latest AI feature
ASX-listed Alcidion has secured regulatory approvals in Australia and the UK for its latest AI-assisted tool for analysing doctors' free-text notes.
It has registered the Miya Precision Concept Detection capability with Australia's Therapeutic Goods Administration register and the UK Medicines and Healthcare products Regulatory Agency.
Based on its corporate announcement, the AI tool, embedded within the Miya Noting module of the Miya Precision platform, analyses doctors' free-text notes to identify medical concepts and suggest associated SNOMED CT codes, with all outputs requiring clinician validation before inclusion in the patient record.
Alcidion said the AI feature will be offered as an optional module supported by the company's proprietary Miya AI Service for secure AI deployment in healthcare environments.
NSW Health launches vaccination schedule tool
NSW Health has launched a personalised childhood vaccination schedule tool amid rising measles cases.
The digital tool, according to a media statement, generates a customised vaccination schedule based on a child's date of birth and includes an "add to calendar" function that automatically sets reminders one week before and on the due date, supporting timely uptake of vaccines provided free across NSW for diseases, including measles, mumps, rubella, polio, and whooping cough.
The tool was informed by a NSW Health-commissioned research that found parents often feel uncertain or overwhelmed about the immunisation schedule. It is part of broader efforts to lift coverage rates further beyond 90% of children currently fully immunised in the state.
Diabetes Australia backs AI projects
This year, Diabetes Australia will invest A$2 million ($1.4 million) through its research trust to fund 19 projects, including several AI initiatives, aimed at reducing diabetes complications and improving care across Australia.
Among the funded work are AI-based projects to develop tools that generate clear-language healthcare summaries, support self-management, and strengthen connections between patients and care teams.
These include a University of Sydney-led effort to co-design an AI system that produces health-literate summaries of personalised diabetes care advice.
